Skip to main content

Table 1 Baseline patient characteristics

From: Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE

Characteristic

SZC (n = 97)

Placebo (n = 99)

Age, years, mean (SD)

55.7 (13.8)

60.4 (13.2)

Sex, male, n (%)

57 (58.8)

58 (58.6)

Race, n (%)

 White

50 (51.5)

52 (52.5)

 Black or African American

11 (11.3)

8 (8.1)

 Asian

33 (34.0)

33 (33.3)

 American Indian or Alaska Native

1 (1.0)

2 (2.0)

 Other

2 (2.1)

4 (4.0)

Height, cm, mean (SD)

166.4 (9.9)

165.1 (9.2)

Weight, kg, mean (SD)

72.0 (22.0)

70.0 (15.9)

BMI, kg/m2, mean (SD)

26.9 (7.1)

26.7 (5.4)

Pre-dialysis serum potassium concentration, mmol/L, mean (SD)a

5.8 (0.6)

5.9 (0.6)

Dialysis history

 Vintage, years, mean (SD)

8.0 (6.1)

7.8 (7.6)

 Access type, n (%)

  Arteriovenous fistula

84 (87.5)

90 (90.9)

  Arteriovenous graft

7 (7.3)

3 (3.0)

  Tunneled central venous catheter

4 (4.2)

6 (6.1)

  Other

1 (1.0)

0 (0.0)

  Total

96 (100.0)

99 (100.0)

Dialysis adequacy

 spKt/V, mean (SD)

1.7 (0.3)

1.7 (0.4)

 Urea removal rate, %, mean (SD)

72.9 (6.7)

74.6 (5.6)

 Dialysate flow, ml/min, mean (SD)

512.0 (162.8)

538.5 (136.0)

 Dialysis potassium concentration, mmol/L

  Mean (SD)

2.26 (0.49)

2.26 (0.47)

  Minimum, maximum

1.0 to 3.0

1.0 to 3.0

 Blood flow, ml/min, mean (SD)

322.0 (110.7)

318.5 (96.3)

  1. Republished with the permission of American Society of Nephrology, from A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia, Fishbane S et al. JASN. Sep 2019;30(9):1723-1733; permission conveyed through Copyright Clearance Center, Inc.
  2. BMI body mass index, SD standard deviation, spKt/V single-pool Kt/V, SZC sodium zirconium cyclosilicate
  3. aVisit 4 (Day 1)